Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Randomised, Double-blind, Parallel-group Study of Alginate Oligosaccharide (OligoG) Dry Powder Inhalation in Addition to Standard of Care Compared to Placebo in Addition to Standard of Care in Patients with Cystic Fibrosis (CF)

NCT03822455 is registered in ClinicalTrials.gov with AlgiPharma AS as lead sponsor.

NCT NCT03822455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03822455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Randomised, Double-blind, Parallel-group Study of Alginate Oligosaccharide (OligoG) Dry Powder Inhalation in Addition to Standard of Care Compared to Placebo in Addition to Standard of Care in Patients with Cystic Fibrosis (CF)
Lead sponsor
AlgiPharma AS
Phase
Phase 2
Overall status
Terminated
Start date
May 16, 2019
Completion date
July 10, 2021
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis